{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:42:51Z","timestamp":1771044171208,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T00:00:00Z","timestamp":1406764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:p>Imatinib mesylate radically changed the natural history of chronic myeloid leukemia (CML). The recent availability of alternative tyrosine kinase inhibitors (TKIs) renders the clinical management of CML more complex. In this article, we summarize our long\u2010term single institution experience. From 2003 to 2012, 102 patients with newly diagnosed chronic phase CML were referred to our institution and treated with imatinib mesylate as first\u2010line therapy. All patients were followed inside a dedicated CML clinic. At 1 year, 82\/95 patients (86.3%) achieved complete cytogenetic response (CCyR) using a treatment performed analysis (TPA); when using an intention to treat analysis, 85\/102 patients (83.3%) obtained CCyR. At 3 months, 58 patients (64.4% TPA) obtained a BCR\u2010ABL transcripts level &lt;10%. A major molecular response (MMR) was obtained by 38% and 53% of patients at 1 and 2 years. Twenty patients (19.6%) discontinued treatment with imatinib; six of them did so in the initial 2 years of treatment (4 for resistance and 2 for adverse events). We observed seven deaths (6.86%). Overall survival (OS) at 6 years is 95.1% (95% C.I. 90\u2013100%) and is not different from that of the general population. No patient experienced progression of disease (95% C.I.: 0\u20133%). Our results suggest that patient management is a crucial point to obtain a successful therapeutic outcome: at 1 year CCyR and MMR rates are similar to the results obtained with second generation TKIs and OS is not different from that of the general population.Am. J. Hematol. 89:E184\u2013E187, 2014. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23804","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T19:03:24Z","timestamp":1405451004000},"source":"Crossref","is-referenced-by-count":20,"title":["First\u2010line treatment of 102 chronic myeloid leukemia patients with imatinib: A long\u2010term single institution analysis"],"prefix":"10.1002","volume":"89","author":[{"given":"Ilaria","family":"Vigan\u00f2","sequence":"first","affiliation":[{"name":"Department of Health Sciences University of Milano\u2010Bicocca via Cadore 48 Monza Italy"},{"name":"San Gerardo Hospital Clinical Research Unit Monza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunzio","family":"Di Giacomo","sequence":"additional","affiliation":[{"name":"San Gerardo Hospital Clinical Research Unit Monza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Bozzani","sequence":"additional","affiliation":[{"name":"San Gerardo Hospital Clinical Research Unit Monza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Antolini","sequence":"additional","affiliation":[{"name":"Department of Health Sciences University of Milano\u2010Bicocca via Cadore 48 Monza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[{"name":"Department of Health Sciences University of Milano\u2010Bicocca via Cadore 48 Monza Italy"},{"name":"San Gerardo Hospital Clinical Research Unit Monza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Gambacorti Passerini","sequence":"additional","affiliation":[{"name":"Department of Health Sciences University of Milano\u2010Bicocca via Cadore 48 Monza Italy"},{"name":"San Gerardo Hospital Clinical Research Unit Monza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq201"},{"key":"e_1_2_6_3_1","first-page":"1013","article-title":"Chromosome studies in human leukemia. II. Chronic granulocytic leukemia","volume":"27","author":"Nowell PC","year":"1961","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/315758a0"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90438-0"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2002.1.111"},{"key":"e_1_2_6_8_1","first-page":"1126","article-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8\u2010Year Follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib","author":"Deininger M","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.6962"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21942"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23804","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:50:04Z","timestamp":1696589404000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,31]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1002\/ajh.23804"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23804","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,31]]}}}